金十数据5月13日讯，华兰股份晚间公告，公司控股股东江阴华兰机电科技有限公司、实控人（华一 敏、华国平、杨菊兰）自愿承诺：自承诺公告之日起12个月内，不以任何形式减持本股东直接和间接持 有的公司股票；承诺期内如发生资本公积转增股本、派送股票红利、配股、增发等产生的股份，亦遵守 上述承诺。 华兰股份：控股股东、实控人承诺12个月内不减持公司股份 ...

关于公司控股股东、实际控制人自愿承诺不减持公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）于近日收到了公司控股 股东江阴华兰机电科技有限公司、实际控制人（华一敏先生、华国平先生、杨菊兰女 士）出具的《关于自愿承诺不减持的承诺函》，现将具体内容公布如下： 一、本次承诺的主要内容 基于对公司未来发展前景的信心以及内在价值的认可，为支持公司持续、稳定、 健康发展，同时为增强广大投资者信心，切实维护投资者权益和资本市场的稳定，本 人/本公司自愿承诺：自本承诺公告之日起 12 个月内，不以任何形式减持本股东直接 和间接持有的公司股票；承诺期内如发生资本公积转增股本、派送股票红利、配股、 增发等产生的股份，亦遵守上述承诺。若违反上述承诺，减持股份所得的收益全部归 公司所有，并依法承担由此产生的法律责任。 证券代码：301093 证券简称：华兰股份 公告编号：2025-042 江苏华兰药用新材料股份有限公司 三、其他说明 公司董事会将监督上述相关人员严格遵守承诺。若上述相关人员未遵守相关承 诺，公司董事会将保 ...

证券代码：301093 证券简称：华兰股份 江苏华兰药用新材料股份有限公司 3.请问公司2025年上半年的业绩大概怎么样？ 答：投资者您好！公司目前生产经营状况良好，2025年半年度业 绩情况请关注后续披露的半年度报告。谢谢！ 投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 形式 ☐现场 网上 ☐电话会议 参与单位名称及人员姓名 线上参与公司2024年度网上业绩说明会的全体投资者 时间 2025年05月13日15:00-16:00 地点 价值在线（https://www.ir-online.cn/），采用网络文字互动方式 举行 上市公司接待人员姓名 董事长兼总经理 华一敏先生 独立董事 徐作骏先生 保荐代表人 邹晓东先生 副总经理、董事会秘书 刘雪女士 副总经理、财务总监 徐立中先生 投资者关系活动 主要内容介绍 一、 公司介绍 二、 互动交流环节 1.公司2024年度分红情况是怎么样的？ 答：投资者您好！经公司董事会审议通过的2024年度利润分配预 案如下：以公司现有总股本126,308,942股为基数，拟向全 ...

证券代码：301093 证券简称：华兰股份 公告编号：2025-041 江苏华兰药用新材料股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： "公司""华兰股份"或"发行人"）首次公开发行前部分已发行股份。 期为 2025 年 5 月 15 日（星期四）。 一、公司首次公开发行股票和股本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意江苏华 兰 药 用 新 材 料 股 份 有 限 公 司 首 次 公 开 发 行 股 票 注 册 的 批 复 》（ 证 监 许 可 20213020 号）同意注册，公司首次公开发行人民币普通股（A 股）33,666,667 股，并于 2021 年 11 月 1 日在深圳证券交易所上市交易。公司首次公开发行后总 股本为 134,666,667 股，其中有限售条件流通股 103,765,403 股，占发行后总股 本的比例为 77.05%；无限售条件流通股 30,901,264 股，占发行后总股本的比例 为 22.95%。2022 年 5 月 10 日，公司首次公开发行网下配售限售股上市流通， ...

Core Viewpoint - The report outlines the approval and details regarding the lifting of restrictions on shares of Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. prior to its initial public offering (IPO) and the subsequent listing of these shares for trading [1][2]. Summary by Sections 1. Type of Restricted Shares - The company issued 33,666,667 shares during its IPO, with a total share capital of 134,666,667 shares post-IPO. Of these, 103,765,403 shares were subject to restrictions, representing 77.05% of the total. The current release involves 1,756,450 shares, accounting for 1.30% of the total share capital [1][2]. 2. Changes in Share Capital - Following the issuance of restricted shares, the total share capital increased to 135,786,667 shares after the granting of 1,120,000 restricted shares on March 16, 2023. The company also canceled 6,412,625 shares held in a repurchase account, leading to a total of 126,308,942 shares as of the report date [3][4]. 3. Commitments and Compliance - The controlling shareholder, Jiangyin Hualan Electromechanical Technology Co., Ltd., committed to not pledging or transferring shares for 36 months post-IPO. If the stock price falls below the IPO price for 20 consecutive trading days, the lock-up period is extended by 6 months. All commitments have been adhered to without any violations [5][6][9]. 4. Listing and Trading Arrangements - The shares will be available for trading starting May 15, 2025. A total of 37,827,846 shares will be released, which is 29.9487% of the total share capital. The release involves four shareholders, with no shares being pledged or frozen [10][12]. 5. Share Structure Post-Release - After the release of restricted shares, the structure will reflect 38,032,821 restricted shares (30.11%) and 126,103,967 unrestricted shares (99.84%). The total share capital remains at 126,308,942 shares [11][12]. 6. Sponsor's Verification Opinion - The sponsor confirms that all shareholders have complied with their lock-up commitments and that the application for the release of restricted shares meets all regulatory requirements. The information disclosed regarding the release is deemed accurate and complete [13].

证券代码：301093 证券简称：华兰股份 公告编号：2025-041 江苏华兰药用新材料股份有限公司 首次公开发行前已发行股份部分解除限售并上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次解除限售的股份为江苏华兰药用新材料股份有限公司（以下简称 "公司""华兰股份"或"发行人"）首次公开发行前部分已发行股份。 2、本次解除限售股东户数共计 4 户，本次限售股上市流通数量为 37,827,846 股，占公司股本总数的 29.9487%，本次解除限售的股份上市流通日 期为 2025 年 5 月 15 日（星期四）。 一、公司首次公开发行股票和股本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意江苏华 兰药用新材料股份有限公司首次公开发行股票注册的批复》（证监许可 [2021]3020 号）同意注册，公司首次公开发行人民币普通股（A 股）33,666,667 股，并于 2021 年 11 月 1 日在深圳证券交易所上市交易。公司首次公开发行后总 股本为 134,666,667 股，其中有限售条件流通股 ...

Group 1 - Baichuan Energy plans to reduce its shareholding by up to 26.82 million shares, accounting for 2% of the total share capital, due to personal investment and funding needs [1] - Jinhong Gas intends to distribute a cash dividend of 1.00 yuan per 10 shares, with the record date on May 15, 2025 [2] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1% of the total share capital due to liquidity needs [2][3] Group 2 - Jiadu Technology will cancel 10.20 million repurchased shares, reducing its total share capital from 2.143 billion shares to 2.133 billion shares [4] - ILE Home's shareholder plans to reduce its stake by up to 154,250 shares, accounting for 0.4778% of the total share capital, due to funding needs [5] - Lai Yifen has fully removed related batches of its honey date dumpling products from shelves due to consumer health concerns [6][7] Group 3 - CATL's vice chairman Li Ping and spouse plan to donate 4.05 million shares to Fudan University for establishing a research fund, reducing Li Ping's shareholding from 4.58% to 4.48% [8] - Shuanghuan Transmission's shareholders completed their reduction plan, selling a total of 6.69 million shares, accounting for 0.789% of the total share capital [9] - Chengfei Integration reported no significant changes in its business operations or external environment despite stock price fluctuations [10] Group 4 - Guizhou Tire's controlling shareholder plans to increase its stake by no less than 50 million yuan and no more than 100 million yuan within six months [11] - *ST Youshu's application to revoke the delisting risk warning has been approved, and its stock will resume trading under a new name [13] - Jingwei Huikai's shareholders plan to reduce their stake by up to 3% of the total share capital due to funding needs [14] Group 5 - Hualan Biological's major shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [15] - Huyou Pharmaceutical's shareholder plans to reduce its stake by up to 2.997% of the total share capital due to funding needs [16] - Dongpeng Holdings' shareholders plan to reduce their stake by up to 1.5% of the total share capital due to funding needs [17] Group 6 - Keleke's controlling shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [18] - Dongfang Ocean's major shareholder plans to reduce its stake by 1% of the total share capital due to investor redemption requests [19] - Yisheng Shares reported a sales revenue of 141 million yuan from white feather chicken seedlings in April, with a year-on-year decrease of 7.28% [20] Group 7 - Qujiang Cultural Tourism's controlling shareholder's 12 million shares are set to be auctioned due to contractual disputes, representing 4.70% of the total share capital [21] - Duople's shareholder plans to reduce its stake by up to 123,800 shares, accounting for 2% of the total share capital, due to personal funding needs [22][23]

Group 1 - The major shareholder, Ruizhong Life Insurance Co., Ltd., plans to reduce its stake in Hualan Co., Ltd. by up to 3,789,267 shares, representing 3.00% of the total share capital, within a three-month period starting from June 4, 2025 [1] - The reduction will occur through centralized bidding and block trading, with a maximum of 1,263,089 shares (1.00% of total share capital) to be sold via centralized bidding and 2,526,178 shares (2.00% of total share capital) via block trading [1] - Ruizhong Life Insurance is the second-largest shareholder of Hualan Co., Ltd., holding 21,956,522 shares, which accounts for 17.38% of the company's total share capital [2] Group 2 - Hualan Co., Ltd. was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2021, with an initial public offering of 33,666,667 shares at a price of 58.08 yuan per share, raising a total of 1.955 billion yuan [2] - The net proceeds from the IPO amounted to 1.804 billion yuan, exceeding the original plan by 1.254 billion yuan, which was intended for automation and intelligent factory renovation, research and development center construction, and working capital [2] - The total issuance costs for Hualan Co., Ltd. were 151 million yuan, with Huatai United Securities Co., Ltd. receiving 133 million yuan as underwriting and sponsorship fees [3]

Group 1 - The private equity issuance market has seen a significant increase in activity, with nearly 3,500 new private securities investment funds registered this year, representing a nearly 40% growth compared to the same period last year [1] - NIO plans to issue H-shares at a maximum price of 263 HKD per share, with the pricing expected between May 13 and May 16, and trading to commence on May 20 [1] - A trend of consumer companies going public overseas has emerged, with several new consumption brands planning listings in Hong Kong and the US, driven by the need for international expansion and brand enhancement [1] Group 2 - Shanghai Ladder Medical Technology has successfully conducted a clinical trial of an invasive brain-computer interface system, allowing a participant to control a game using thoughts after implant surgery [2] - Samsung has reportedly reached an agreement with major clients to increase DRAM prices, with DDR4 prices rising by double-digit percentages and DDR5 prices increasing by single-digit percentages [2] - Polestar is recalling 3,664 vehicles in the US due to a rearview camera issue that may reduce driver visibility, with software updates planned to address the problem [2] Group 3 - Specialized Medical Company in Saudi Arabia successfully completed a $500 million IPO, with all shares sold within hours, indicating strong demand [3] - Mirxes Holding Company Limited has passed the listing hearing at the Hong Kong Stock Exchange, focusing on miRNA technology for cancer screening [4] Group 4 - Huiyuan Juice has issued a statement refuting rumors about its financial difficulties, emphasizing that such claims are malicious and damaging to its reputation [5] - Hualan Biological Engineering announced that its major shareholder plans to reduce its stake by up to 3% within three months [6] - Pilin Bio received an administrative regulatory decision from the Shanxi Securities Regulatory Bureau due to internal control deficiencies and inaccurate information disclosure [7] Group 5 - ST Jinke has received court approval for its restructuring plan, allowing the company and its subsidiary to enter the execution phase of the plan [8]